Louisa Delaney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Louisa Delaney has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Sophie Relph
Royal College of Obstetricians and Gynaecologists London UK
2 shared publications Alessandro Alagna
Affiliation London Perinatal Morbidity and Mortality Working Group (NHS), London, United Kingdom
1 shared publication- Andrew Copas
Institute for Global Health, University College London, London, UK
1 shared publication - Andrew H. Shennan
Department of Women and Children's Health St Thomas' Hospital, King's College London London UK
1 shared publication - Andrew Healey
King’s College London
1 shared publication - Annette Briley
Caring Futures Institute, College of Nursing and Health Sciences, Flinders University, Adelaide, Australia
1 shared publication
Latest Publications
- Open Access
- 21 June 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (6) , e1004004
Evaluation of the Growth Assessment Protocol (GAP) for antenatal detection of small for gestational age: The DESiGN cluster randomised trial
Background: Antenatal detection and management of small for gestational age (SGA) is a strategy to reduce stillbirth. Large observational studies provide conflicting results on the effect of the Growth Assessment Protocol (GAP) in relation to detection of SGA and reduction of stillbirth; to the best of our knowledge, there are no reported randomised control trials. Our aim was to determine if GAP improves antenatal detection of SGA compared to standard care. Methods and findings: This was a pragmatic, superiority, 2-arm, parallel group, open, cluster randomised control trial. Maternity units in England were eligible to participate in the study, except if they had already implemented GAP. All women who gave birth in participating clusters (maternity units) during the year prior to randomisation and during the trial (November 2016 to February 2019) were included. Multiple pregnancies, fetal abnormalities or births before 24+1 weeks were excluded. Clusters were randomised to immediate implementation of GAP, an antenatal care package aimed at improving detection of SGA as a means to reduce the rate of stillbirth, or to standard care. Randomisation by random permutation was stratified by time of study inclusion and cluster size. Data were obtained from hospital electronic records for 12 months prerandomisation, the washout period (interval between randomisation and data collection of outcomes), and the outcome period (last 6 months of the study). The primary outcome was ultrasound detection of SGA (estimated fetal weight p = 0.62). Findings were consistent in full ITT analysis. Fidelity and dose of GAP implementation were variable, while a high proportion (88.7%) of women were reached. Use of routinely collected data is both a strength (cost-efficient) and a limitation (occurrence of missing data); the modest number of clusters limits our ability to study small effect sizes. Conclusions: In this study, we observed no effect of GAP on antenatal detection of SGA compared to standard care. Given variable implementation observed, future studies should incorporate standardised implementation outcomes such as those reported here to determine generalisability of our findings. Trial registration: This trial is registered with the ISRCTN registry, ISRCTN67698474.
- 21 June 2022
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 19 (6) , e1004004
Open AccessEvaluation of the Growth Assessment Protocol (GAP) for antenatal detection of small for gestational age: The DESiGN cluster randomised trial
Background: Antenatal detection and management of small for gestational age (SGA) is a strategy to reduce stillbirth. Large observational studies provide conflicting results on the effect of the Growth Assessment Protocol (GAP) in relation to detection of SGA and reduction of stillbirth; to the best of our knowledge, there are no reported randomised control trials. Our aim was to determine if GAP improves antenatal detection of SGA compared to standard care. Methods and findings: This was a pragmatic, superiority, 2-arm, parallel group, open, cluster randomised control trial. Maternity units in England were eligible to participate in the study, except if they had already implemented GAP. All women who gave birth in participating clusters (maternity units) during the year prior to randomisation and during the trial (November 2016 to February 2019) were included. Multiple pregnancies, fetal abnormalities or births before 24+1 weeks were excluded. Clusters were randomised to immediate implementation of GAP, an antenatal care package aimed at improving detection of SGA as a means to reduce the rate of stillbirth, or to standard care. Randomisation by random permutation was stratified by time of study inclusion and cluster size. Data were obtained from hospital electronic records for 12 months prerandomisation, the washout period (interval between randomisation and data collection of outcomes), and the outcome period (last 6 months of the study). The primary outcome was ultrasound detection of SGA (estimated fetal weight p = 0.62). Findings were consistent in full ITT analysis. Fidelity and dose of GAP implementation were variable, while a high proportion (88.7%) of women were reached. Use of routinely collected data is both a strength (cost-efficient) and a limitation (occurrence of missing data); the modest number of clusters limits our ability to study small effect sizes. Conclusions: In this study, we observed no effect of GAP on antenatal detection of SGA compared to standard care. Given variable implementation observed, future studies should incorporate standardised implementation outcomes such as those reported here to determine generalisability of our findings. Trial registration: This trial is registered with the ISRCTN registry, ISRCTN67698474.
- Open Access
- 22 November 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (11) , e1003856
Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis
Background: The rise in the global prevalence of diabetes, particularly among younger people, has led to an increase in the number of pregnant women with preexisting diabetes, many of whom have diabetes-related microvascular complications. We aimed to estimate the magnitude of the risks of adverse pregnancy outcomes or disease progression in this population.Methods and findings: We undertook a systematic review and meta-analysis on maternal and perinatal complications in women with type 1 or 2 diabetic microvascular disease and the risk factors for worsening of microvascular disease in pregnancy using a prospective protocol (PROSPERO CRD42017076647). We searched major databases (January 1990 to July 2021) for relevant cohort studies. Study quality was assessed using the Newcastle–Ottawa Scale. We summarized the findings as odds ratios (ORs) with 95% confidence intervals (CIs) using random effects meta-analysis. We included 56 cohort studies involving 12,819 pregnant women with diabetes; including 40 from Europe and 9 from North America. Pregnant women with diabetic nephropathy were at greater risk of preeclampsia (OR 10.76, CI 6.43 to 17.99,p< 0.001), early (p< 0.001) and any preterm birth (OR 4.48, CI 3.40 to 5.92,p< 0.001), and cesarean section (OR 3.04, CI 1.24 to 7.47,p= 0.015); their babies were at higher risk of perinatal death (OR 2.26, CI 1.07 to 4.75,p= 0.032), congenital abnormality (OR 2.71, CI 1.58 to 4.66,p< 0.001), small for gestational age (OR 16.89, CI 7.07 to 40.37,p< 0.001), and admission to neonatal unit (OR 2.59, CI 1.72 to 3.90,p< 0.001) compared to those without nephropathy. Diabetic retinopathy was associated with any preterm birth (OR 1.67, CI 1.27 to 2.20,p< 0.001) and preeclampsia (OR 2.20, CI 1.57 to 3.10,p< 0.001) but not other complications. The risks of onset or worsening of retinopathy were increased in women who were nulliparous (OR 1.75, 95% CI 1.28 to 2.40,p< 0.001), smokers (OR 2.31, 95% CI 1.25 to 4.27,p= 0.008), with existing proliferative disease (OR 2.12, 95% CI 1.11 to 4.04,p= 0.022), and longer duration of diabetes (weighted mean difference: 4.51 years, 95% CI 2.26 to 6.76,p< 0.001) compared to those without the risk factors. The main limitations of this analysis are the heterogeneity of definition of retinopathy and nephropathy and the inclusion of women both with type 1 and type 2 diabetes.Conclusions: In pregnant women with diabetes, presence of nephropathy and/or retinopathy appear to further increase the risks of maternal complications.
- 22 November 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (11) , e1003856
Open AccessAdverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis
Background: The rise in the global prevalence of diabetes, particularly among younger people, has led to an increase in the number of pregnant women with preexisting diabetes, many of whom have diabetes-related microvascular complications. We aimed to estimate the magnitude of the risks of adverse pregnancy outcomes or disease progression in this population.Methods and findings: We undertook a systematic review and meta-analysis on maternal and perinatal complications in women with type 1 or 2 diabetic microvascular disease and the risk factors for worsening of microvascular disease in pregnancy using a prospective protocol (PROSPERO CRD42017076647). We searched major databases (January 1990 to July 2021) for relevant cohort studies. Study quality was assessed using the Newcastle–Ottawa Scale. We summarized the findings as odds ratios (ORs) with 95% confidence intervals (CIs) using random effects meta-analysis. We included 56 cohort studies involving 12,819 pregnant women with diabetes; including 40 from Europe and 9 from North America. Pregnant women with diabetic nephropathy were at greater risk of preeclampsia (OR 10.76, CI 6.43 to 17.99,p< 0.001), early (p< 0.001) and any preterm birth (OR 4.48, CI 3.40 to 5.92,p< 0.001), and cesarean section (OR 3.04, CI 1.24 to 7.47,p= 0.015); their babies were at higher risk of perinatal death (OR 2.26, CI 1.07 to 4.75,p= 0.032), congenital abnormality (OR 2.71, CI 1.58 to 4.66,p< 0.001), small for gestational age (OR 16.89, CI 7.07 to 40.37,p< 0.001), and admission to neonatal unit (OR 2.59, CI 1.72 to 3.90,p< 0.001) compared to those without nephropathy. Diabetic retinopathy was associated with any preterm birth (OR 1.67, CI 1.27 to 2.20,p< 0.001) and preeclampsia (OR 2.20, CI 1.57 to 3.10,p< 0.001) but not other complications. The risks of onset or worsening of retinopathy were increased in women who were nulliparous (OR 1.75, 95% CI 1.28 to 2.40,p< 0.001), smokers (OR 2.31, 95% CI 1.25 to 4.27,p= 0.008), with existing proliferative disease (OR 2.12, 95% CI 1.11 to 4.04,p= 0.022), and longer duration of diabetes (weighted mean difference: 4.51 years, 95% CI 2.26 to 6.76,p< 0.001) compared to those without the risk factors. The main limitations of this analysis are the heterogeneity of definition of retinopathy and nephropathy and the inclusion of women both with type 1 and type 2 diabetes.Conclusions: In pregnant women with diabetes, presence of nephropathy and/or retinopathy appear to further increase the risks of maternal complications.